← Leaderboards
Electron Kebebew
University Of California, San Francisco
$690,672
Attributed
$690,672
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $223.7K · FY2006–24$250K$187.5K$125K$62.5K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$690,672 · 2
By mechanism
R21$690,672 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Onur Cil$2,779,607
- Susan Halabi$7,630,539
Others in their field
Top investigators on “Malignant Neoplasm Of Thyroid”
- David Heimbrook · Leidos Biomedical Research, Inc.$89,819,252
- James A Fagin · Sloan-Kettering Inst Can Research$18,343,965
- Keri Hammel · The Emmes Company, Llc$17,992,237
- Stanley R Hamilton · Johns Hopkins University$17,360,724
- Larry Arthur$15,377,757
- Ignacio I. Wistuba · Ut Southwestern Medical Center$15,303,923
Research focus
Malignant Neoplasm Of ThyroidMalignant Endocrine Gland NeoplasmStrategic PlanningMalignant NeoplasmsDiagnosisThyroid GlandUnited StatesEarly DiagnosisOutcome ForecastTumorCancer DiagnosisCancer CareGenesFamilyEndocrine Gland NeoplasmsEndocrineAdrenocortical CarcinomaGeneticBaseOperative Surgical ProceduresGenomicsPathway InteractionsFollow-UpAdrenal Glands
Grant awards (40)
Targeting Ferroptosis in BRAF (V600E) Mutant Anaplastic Thyroid Cancer$178,238
R21 · FY2024 · CA · contact PI
Targeting Ferroptosis in BRAF (V600E) Mutant Anaplastic Thyroid Cancer$223,693
R21 · FY2023 · CA · contact PI
EOB Clinical Core$850,409
ZID · FY2018 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$850,409
ZIA · FY2018 · CA · contact PI
EOB Clinical and Research Fellowship Training Program$748,360
ZIE · FY2018 · CA · contact PI
Clinical and genetic studies in familial nonmedullary thyroid cancer (FNMTC)$476,230
ZIA · FY2018 · CA · contact PI
Genomic and genetic studies of endocrine cancers$476,230
ZIA · FY2018 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$1,040,568
ZIA · FY2017 · CA · contact PI
EOB Clinical Core$1,040,568
ZID · FY2017 · CA · contact PI
EOB Clinical and Research Fellowship Training Program$915,700
ZIE · FY2017 · CA · contact PI
Genomic and genetic studies of endocrine cancers$582,719
ZIA · FY2017 · CA · contact PI
Clinical and genetic studies in familial nonmedullary thyroid cancer (FNMTC)$582,719
ZIA · FY2017 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$997,075
ZIA · FY2016 · CA · contact PI
EOB Clinical Core$997,075
ZID · FY2016 · CA · contact PI
EOB Clinical and Research Fellowship Training Program$877,426
ZIE · FY2016 · CA · contact PI
Genomic and genetic studies of endocrine cancers$558,362
ZIA · FY2016 · CA · contact PI
Clinical and genetic studies in familial nonmedullary thyroid cancer (FNMTC)$558,362
ZIA · FY2016 · CA · contact PI
EOB Clinical and Research Fellowship Training Program$1,152,095
ZIE · FY2015 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$960,079
ZIA · FY2015 · CA · contact PI
EOB Clinical Core$614,450
ZID · FY2015 · CA · contact PI
Genomic and genetic studies of endocrine cancers$576,047
ZIA · FY2015 · CA · contact PI
Clinical and genetic studies in familial nonmedullary thyroid cancer (FNMTC)$537,644
ZIA · FY2015 · CA · contact PI
EOB Clinical Core$1,268,643
ZID · FY2014 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$1,189,352
ZIA · FY2014 · CA · contact PI
Genomic and genetic studies of endocrine cancers$1,189,352
ZIA · FY2014 · CA · contact PI
Clinical and genetic studies in familial nonmedullary thyroid cancer (FNMTC)$317,161
ZIA · FY2014 · CA · contact PI
Gene expression and regulation in endocrine cancers$1,541,934
ZIA · FY2013 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$1,233,547
ZIA · FY2013 · CA · contact PI
Clinical and genetic studies in familial nonmedullary thyroid cancer (FNMTC)$308,387
ZIA · FY2013 · CA · contact PI
Gene expression and regulation in endocrine cancers$1,088,656
ZIA · FY2012 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$870,926
ZIA · FY2012 · CA · contact PI
Clinical and genetic studies in familial nonmedullary thyroid cancer (FNMTC)$217,731
ZIA · FY2012 · CA · contact PI
Gene expression and regulation in endocrine cancers$995,246
ZIA · FY2011 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$796,197
ZIA · FY2011 · CA · contact PI
Clinical and genetic studies in familial nonmedullary thyroid cancer (FNMTC)$199,049
ZIA · FY2011 · CA · contact PI
Gene expression and regulation in endocrine cancers$1,145,102
ZIA · FY2010 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$916,081
ZIA · FY2010 · CA · contact PI
Clinical and genetic studies in familial nonmedullary thyroid cancer (FNMTC)$229,021
ZIA · FY2010 · CA · contact PI
Extracellular matrix and protease markers of malignant thyroid neoplasm$142,480
R21 · FY2007 · CA · contact PI
Extracellular matrix and protease markers of malignant thyroid neoplasm$146,261
R21 · FY2006 · CA · contact PI